Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2015 1
2016 3
2018 7
2019 7
2020 6
2021 13
2022 13
2023 11
2024 21
2025 16
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean longdong zheng (22 results)?
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.
Qin J, Xue L, Hao A, Guo X, Jiang T, Ni Y, Liu S, Chen Y, Jiang H, Zhang C, Kang M, Lin J, Li H, Li C, Tian H, Li L, Fu J, Zhang Y, Ma J, Wang X, Fu M, Yang H, Yang Z, Han Y, Chen L, Tan L, Dai T, Liao Y, Zhang W, Li B, Chen Q, Guo S, Qi Y, Wei L, Li Z, Tian Z, Kang X, Zhang R, Li Y, Wang Z, Chen X, Hou Z, Zheng R, Zhu W, He J, Li Y. Qin J, et al. Among authors: zheng r. Nat Med. 2024 Sep;30(9):2549-2557. doi: 10.1038/s41591-024-03064-w. Epub 2024 Jul 2. Nat Med. 2024. PMID: 38956195 Free PMC article. Clinical Trial.
Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05).
Li C, Tian Y, Zheng Y, Yuan F, Shi Z, Yang L, Chen H, Jiang L, Wang X, Zhao P, Zhang B, Wang Z, Zhao Q, Dong J, Lian C, Xu S, Zhang A, Zheng Z, Wang K, Dang C, Wu D, Chen J, Xue Y, Liang B, Cheng X, Wang Q, Chen L, Xia T, Liu H, Xu D, Zhuang J, Wu T, Zhao X, Wu W, Wang H, Peng J, Hou Z, Zheng R, Chen Y, Yin K, Zhu Z. Li C, et al. Among authors: zheng r. J Clin Oncol. 2025 Feb;43(4):464-474. doi: 10.1200/JCO.24.00795. Epub 2024 Oct 9. J Clin Oncol. 2025. PMID: 39383487 Free PMC article. Clinical Trial.
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction.
Tang Z, Wang Y, Liu D, Wang X, Xu C, Yu Y, Cui Y, Tang C, Li Q, Sun J, Zhang Q, Ji Y, Ma G, Li H, Shen Z, Shen K, Zheng R, Hou Z, Liu T, Wang J, Sun Y. Tang Z, et al. Among authors: zheng r. Nat Commun. 2022 Nov 10;13(1):6807. doi: 10.1038/s41467-022-34403-5. Nat Commun. 2022. PMID: 36357415 Free PMC article. Clinical Trial.
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706).
Zhao H, Yao W, Min X, Gu K, Yu G, Zhang Z, Cui J, Miao L, Zhang L, Yuan X, Fang Y, Fu X, Hu C, Zhu X, Fan Y, Yu Q, Wu G, Jiang O, Du X, Liu J, Gu W, Hou Z, Wang Q, Zheng R, Zhou X, Zhang L. Zhao H, et al. Among authors: zheng r. J Thorac Oncol. 2021 Sep;16(9):1533-1546. doi: 10.1016/j.jtho.2021.05.006. Epub 2021 May 24. J Thorac Oncol. 2021. PMID: 34033974 Free article. Clinical Trial.
Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial.
Zhao Y, Li D, Zhuang J, Li Z, Xia Q, Li Z, Yu J, Wang J, Zhang Y, Li K, Xu S, Li S, Ma P, Cao Y, Liu C, Xu C, Liu Z, Wei J, Zhang C, Qiao L, Gao X, Hou Z, Liu C, Zheng R, Wang D, Liu Y. Zhao Y, et al. Among authors: zheng r. Clin Transl Med. 2024 May;14(5):e1674. doi: 10.1002/ctm2.1674. Clin Transl Med. 2024. PMID: 38685486 Free PMC article. Clinical Trial.
First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study.
Chen X, Xu H, Chen X, Xu T, Tian Y, Wang D, Guo F, Wang K, Jin G, Li X, Wang R, Li F, Ding Y, Tang J, Fang Y, Zhao J, Liu L, Ma L, Meng L, Hou Z, Zheng R, Liu Y, Guan N, Zhang B, Tong S, Chen S, Li X, Shu Y. Chen X, et al. Among authors: zheng r. Signal Transduct Target Ther. 2024 Mar 25;9(1):73. doi: 10.1038/s41392-024-01773-9. Signal Transduct Target Ther. 2024. PMID: 38528050 Free PMC article. Clinical Trial.
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study.
Meng X, Wang J, Xia J, Wu T, Luo Z, Hong Y, Lu P, Guo Y, Ji Y, Zhang M, Yang L, Cheng P, Liang W, Shan Z, Zhou Y, Wang M, Lu T, Song M, Zong H, Song L, Wang W, Guan L, Li Y, Xing J, Xing S, Wu H, Chu J, Luo X, Lu Y, Xin D, Li A, Jiang B, Li S, Jiang G, Fan Q, Zhao F, Zheng R, Zhu W, Hou Z, Jia Y, Wang F. Meng X, et al. Among authors: zheng r. Eur J Cancer. 2024 Nov;212:114328. doi: 10.1016/j.ejca.2024.114328. Epub 2024 Sep 12. Eur J Cancer. 2024. PMID: 39307038 Clinical Trial.
95 results